By Jonathan Gardner | May 18, 2026
In a significant milestone for Merck & Co.’s long-term oncology strategy, the pharmaceutical giant announced on Monday positive results from a late-stage clinical trial evaluating its experimental cancer therapy, Sac-TMT. The study, which focused on patients with advanced endometrial cancer, marks the first success among a sprawling program of 17 concurrent Phase 3 trials. As Merck prepares for the eventual patent expiration of its flagship immunotherapy, Keytruda, the successful development of Sac-TMT serves as a critical pillar in the company’s ambitious roadmap to reach $70 billion in annual sales by the next decade.
The Strategic Imperative: Life After Keytruda
For over a decade, Keytruda has stood as a titan in the oncology space. With approvals across 19 distinct cancer types and two historic "tissue-agnostic" indications, it has become one of the best-selling pharmaceuticals in history. However, Merck’s leadership has been transparent about the "Keytruda cliff"—the inevitable point at which the drug’s exclusivity will wane.
Recognizing that no single blockbuster can replicate the sheer clinical breadth of Keytruda, Merck has pivoted toward a "portfolio-first" approach. The company is betting that by assembling a high-impact array of emerging therapies, it can offset potential revenue losses. Sac-TMT, an antibody-drug conjugate (ADC), sits at the center of this transition. By delivering a targeted "toxic punch" directly to tumors expressing the TROP2 protein—a common biomarker in various aggressive malignancies—Merck hopes to address unmet needs in patient populations that have exhausted standard-of-care immunotherapies.
A Chronology of Collaboration and Discovery
The journey of Sac-TMT is inextricably linked to the evolving geopolitical and scientific landscape of global drug discovery.
- Early 2023: Merck finalized a wide-ranging licensing alliance with Sichuan Kelun-Biotech Biopharmaceutical, a Chinese firm that had made significant strides in the ADC space. The deal provided Merck with rights to seven drug prospects, signaling a shift in Western pharma’s reliance on Chinese innovation.
- Late 2024: Following rapid preclinical and early-phase success, Merck initiated an aggressive clinical program, ultimately greenlighting 17 separate late-stage trials to test Sac-TMT across a spectrum of solid tumors, including breast and lung cancers.
- May 2026: Merck unveiled the first data readout from this program. The endometrial cancer trial, which enrolled patients whose disease had progressed despite platinum-based chemotherapy and prior immunotherapy, provided the first major clinical validation for the platform.
- Upcoming (ASCO 2026): Analysts expect further granularity and clinical validation for the drug to be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting, which is widely viewed as the next litmus test for the drug’s potential market dominance.
Supporting Data and Clinical Efficacy
While Merck has not yet released the full dataset, the top-line results are highly encouraging. The company reported that Sac-TMT demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) compared to the current standard of care—specifically, either of two common chemotherapies.
Crucially, patients receiving Sac-TMT also saw higher rates of remission. This is a vital metric for endometrial cancer, a disease where options become increasingly limited once first-line platinum-based therapies fail. Safety, often the "Achilles heel" of ADCs due to their potent nature, was reported as "consistent" with observations from earlier Phase 1 and 2 trials, suggesting that the treatment is well-tolerated by the patient demographic currently being tested.
Trung Huynh, an analyst at RBC Capital Markets, noted that these findings represent an "encouraging reinforcement" of the drug’s safety profile. Huynh remains bullish on the asset, projecting that Sac-TMT could generate approximately $2.6 billion in annual sales by 2030, with that figure ballooning to $7.2 billion by 2034 as the drug potentially secures additional indications in breast and lung cancer.
Official Responses and Industry Outlook
The pharmaceutical industry has been watching Merck’s "China strategy" closely. The success of Sac-TMT validates the trend of U.S. and European drugmakers tapping into Chinese laboratories to fill their pipelines.
"We are seeing a maturation of the ADC space," said a senior oncology researcher unaffiliated with the trial. "Merck’s ability to take an asset from the Kelun-Biotech partnership and execute a 17-trial program with this level of speed is a testament to the company’s clinical trial infrastructure. If the efficacy holds up across the other 16 trials, they have a blockbuster on their hands that rivals the early promise of the original PD-1 inhibitors."
Merck’s leadership remains focused on the broader mission. By targeting TROP2-expressing tumors, the company is positioning itself in a highly competitive arena, but one that is underserved. The data suggests that Sac-TMT is not just a secondary asset but a potential cornerstone of Merck’s oncology franchise.
Implications for Patients and Markets
The implications of this trial extend far beyond Merck’s balance sheet. For patients with advanced, treatment-resistant endometrial cancer, the emergence of a new therapy that demonstrably extends life and increases remission rates offers a vital new lease on life.
Market Dynamics
The financial stakes are immense. Investors have been waiting for a clear sign that Merck’s R&D spend is yielding tangible results that can withstand the scrutiny of regulators and the pressures of the marketplace. The positive readout provides a "proof of concept" for the entire Kelun-Biotech partnership. If Sac-TMT can maintain this momentum, it will likely influence future licensing deals, potentially driving up the valuation of other Chinese-origin ADCs.
The Competitive Landscape
While other companies are also pursuing TROP2-directed therapies, Merck’s massive investment in simultaneous trials provides them with a "first-mover" advantage in gathering data across multiple indications. As the oncology landscape shifts toward precision medicine and personalized, biomarker-driven treatments, Sac-TMT’s ability to target a specific protein while preserving general safety makes it a high-value candidate in the global fight against cancer.
Conclusion: A New Era for Merck
The success of the endometrial cancer trial is more than a single win; it is a fundamental test of Merck’s post-Keytruda strategy. By successfully leveraging international partnerships and executing an ambitious clinical trial program, the company is proving that it can navigate the complexities of modern oncology drug development.
As the medical community prepares to digest the full results at ASCO, the focus will shift to how quickly Merck can move toward regulatory submissions. For now, the sentiment is clear: Merck has successfully cleared its first hurdle, and the path to its $70 billion goal looks significantly more achievable than it did just 48 hours ago. The transition from a "Keytruda company" to a "multi-platform oncology powerhouse" is officially underway, and if the data on Sac-TMT continues to trend positively, the future of the company—and the patients it serves—looks increasingly promising.
